Tag Archive for: semaglutide

Even as they are gathering proof of extensive benefits to patients, the manufacturers of GLP-1s will have to overcome supply chain difficulties and high prices to get payers to fund these medicines for treating obesity.

Two Florida courts last week ruled in Novo Nordisk’s favor in its legal battle against wellness clinics and compounding pharmacies for marketing counterfeit or compounded versions of its popular weight-loss drug semaglutide.

Citing America’s Poison Centers, which represents 55 regional poison centers across the U.S., Reuters revealed that all three incidences of hypoglycemia were detected by the same regional poison control center and that the FDA was investigating these reports.

For this study, published online in the journal Nature and funded by the U.S. National Institutes of Health, researchers reviewed data on 240,258 U.S. patients prescribed Wegovy or other medications for weight loss and nearly 1.6 million with type 2 diabetes prescribed Ozempic or other treatments.

Merck’s experimental drug efinopegdutide, which belongs to the GLP-1 class and is being developed as a treatment for non-alcoholic steatohepatitis (NASH), also showed a “compelling” weight-loss benefit.

Yesterday Novo Nordisk said it sued one compounding pharmacy and refiled a lawsuit against another after finding their products claiming to contain the active ingredient for its in-demand weight-loss drug Wegovy were impure, some by as much as 33%.

Novo Nordisk is diverting manufacturing capacity away from its older GLP-1 drug Victoza in order to cater to sky-high Ozempic demand.

Just a week after it secured FDA approval, Eli Lilly’s Zepbound now faces a challenge from Novo Nordisk’s investigational next-generation weight-loss candidate CagriSema in a Phase III trial.

The company’s shares rose 3% on Monday as the market reacted to data the drugmaker presented over the weekend showing that the heart protective benefits of its popular obesity drug Wegovy are not solely due to weight loss.

Novo Nordisk (wants to buy more companies with drugs in early- to mid-stages of development through “bolt-on” deals of up to a few billion dollars, CEO Lars Fruergaard Jorgensen told Reuters on Friday.